DALE P. DE VORE, PH.D.
`
`Dale P. DeVore is currently serving as a contract Chief Scientific Officer for Sanova
`Bioscience, Inc. and continues to provide regulatory, clinical, and R&D consulting services to the
`pharmaceutical, medical device and tissue engineering industry. Until December 2008, Dr.
`DeVore was Vice President of Research & Development for BioForm Medical, Inc. (now Merz
`Pharmaceuticals), a medical aesthetics company with technology and products in dermatology
`and plastic surgery. Following his tenure at BioForm Medical, Dr. DeVore joined Euclid Systems
`Corporation assuming the role of Chief Scientist to develop novel collagen-based compositions
`for sustained delivery of ocular therapeutic agents. Dr. DeVore is a principal in several start-up
`ventures in the medical device/tissue engineering field. He recently served as a consultant for
`Clear Vascular, a company formed by Essex Woodlands Health Ventures to utilize Tin 117m for
`diagnosis and treatment of vulnerable plaque. He was also Scientific Director for Membrell and
`ECM Technologies, LLC developing and testing processed eggshell membrane to reduce pain
`associated with osteoarthritis. His own company, Xium, LLC was awarded a Phase I SBIR in
`2004 to develop natural polymer systems to deliver drugs to the back of the eye. He was Project
`Director for a major hyaluronic acid manufacturer, Anika Therapeutics, Inc., to develop and
`clinically evaluate a hyaluronate product for soft tissue augmentation. This product gained FDA
`approval in December 2006. Prior to this assignment he was Executive Director of Government
`Programs for a small technology firm developing methods to attach enzymes to the skin surface
`to protect against penetration by nerve agents. Dr. DeVore was the principal investigator on a
`Phase II STTR contract from the Department of the Army. He was co-founder, Chief Scientific
`Officer, Senior Vice President of Research and Development, and a Director at Collagenesis, Inc.,
`a Beverly, MA-based technology company commercializing tissue matrix systems, derived from
`processed human tissues, for use in plastic surgery and dermatology, otolaryngology, urology,
`orthopedics and drug delivery. Dr. DeVore was responsible for all FDA communications and
`submissions. Collagenesis evolved from Autogenesis Technologies, Inc., a small research &
`development company co-founded by Dr. DeVore and Dr. Charles D. Kelman, a world-renowned
`ophthalmologist from New York City. Prior to Autogenesis, Dr. DeVore was Vice President of
`Scientific Affairs at MedChem Products in Woburn, MA. He developed and patented a
`hyaluronic-based product called AMVISC PLUS, coordinated clinical studies, submitted
`appropriate documentation to FDA and obtained FDA clearance for this product now being sold
`by Bausch & Lomb for use as an adjunct to cataract surgery.
`
`
`Dr. DeVore received his Ph.D. in 1973 from Rutgers University in New Brunswick, NJ.
`He subsequently joined Battelle Memorial Institute in Columbus, OH as a Research Biochemist.
`At Battelle, Dr. DeVore was awarded five NIH grants and two Arthritis Foundation grants. The
`latter grants focused on determining the mechanism of action of D-penicillamine as a remission-
`inducing drug to treat rheumatoid arthritis.
`
`In 1979, while a Principle Research Biochemist and Group Leader of Cell & Molecular
`
`Biology at Battelle, he accepted a position with 3M’s Riker Laboratories as a Research Specialist
`and Supervisor of the Connective Tissue Laboratory. Dr. DeVore’s responsibilities were to
`develop in vitro and animal models to evaluate new Riker agents for treatment of rheumatoid
`arthritis. In 1981, he joined the Surgical Products Division to develop biomaterials for ophthalmic
`and orthopedic applications. In 1983 he was promoted to Senior Research Specialist and was
`responsible for programs in Collagen and Biopolymer Technology. From 1981-1985 he also held
`an academic appointment in the School of Dentistry at the University of Minnesota lecturing on
`connective tissue and continuing work on his NIH grant to characterize sea mussel adhesive
`proteins.
`
`Exhibit 1003
`Prollenium v. Allergan
`
`

`

`
`
`
`
`
`
`
`
`
`Dr. DeVore is generally regarded as one of the leading experts in the development,
`
`evaluation, and commercialization of natural polymer-based medical implants. Dr. DeVore has
`authored or co-authored more than 36 issued U.S. patents and more than 100 issued patents
`worldwide. In addition to his patents, he has more than 70 technical publications and several
`hundred technical presentations. He is a member of the Society for Biomaterials and the
`Association for Research in Vision and Ophthalmology and has been a member of American
`College of Rheumatology, American Burn Association, International Ocular Surface Society,
`American Urogynecologic Society and American Association of Tissue Banks. In addition Dr.
`DeVore has served on the Editorial Review Board of the Journal of Long-term Effects of Medical
`Implants. Dr. DeVore is a consultant to two healthcare venture capital organizations and is a
`member of scientific advisory boards. In 2015, Dr. DeVore was honored for "Excellence in
`Medical Device Consulting" by Worldwide Who's Who.
`
`
`
`
`
`
`
`
`
`CV-08/2017
`
`2
`
`

`

`
`
`
`BIOGRAPHICAL SKETCH
`
`
`
`
`
`
`Name: Dale P. DeVore, PhD
`Executive/Consultant to the Pharmaceuticals/Medical Device/Tissue
`Engineering Industry
`
`Address: 3 Warwick Drive, Chelmsford, MA 01824
`
`
`Education:
`
`
`
`
`
`
`
`
`
`Employment:
`
`
`
`Chief Scientific Officer
`
`Sanova Bioscience, Inc.
`
`42 Nagog Park, Suite 110
`
`Acton, MA 01720
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Biochemistry
`
`Biochemistry
`Biochemistry
`
`2016-present
`
`Rutgers University
`New Brunswick, NJ
`Rutgers University
`Rutgers University
`
`
`
`
`
`
`
`
`B.S.
`
`M.S.
`Ph.D.
`
`
`
`
`
`
`
`
`
`
`Chief Scientific Officer and co-inventor of 4 provisional patents describing compositions
`for soft tissue augmentation and for improving skin appearance. Responsible for
`establishing the Sanova Bioscience, Inc. laboratory and for directing all research and
`development.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Chief Scientific Officer
`EternoGen, LLC
`1601 South Providence Road
`Columbia, MO 65211
`
`
`
`
`
`
`
`
`
`
`
`2014-2016
`
`Chief Scientific Officer and co-inventor of Eternogen's novel collagen composition for
`soft tissue augmentation and device coating. Responsible for executive management of
`research and development activities and assisting is regulatory and clinical activities
`including preparing CE mark documents and IDE/PMA documents for FDA review and
`approvals.
`
`
`
`2010-2015
`
`
`
`
`
`
`
`
`
`
`Chief Scientist
`Euclid Systems Corporation
`2776 Towerview Road
`Herndon, VA 20171
`
`Chief Scientist, inventor and principal investigator for an ophthalmology company (1)
`developing biological agents and medical devices for stabilizing the human cornea
`following orthokeratology lens wear and post-LASIK procedures, and for treatment of
`keratoconus and (2) developing and evaluating collagen-based compositions for sustained
`drug delivery of ophthalmic agents to treat glaucoma and age-related macular
`degeneration. Responsible for assisting in the preparation and presentation of IND/NDA
`and IDE/PMA documents for FDA approval of novel biologic agents.
`
`
`CV-08/2017
`
`3
`
`

`

`
`
`
`
`
`
`
`
`
`
`Vice President of Research & Development
`BioForm Medical, Inc. (now Merz Pharmaceuticals)
`4133 Courtney Road, Suite 10
`Franksville, WI 53126
`
`
`
`
`
`2004-2009
`
`Position on a ½ time basis serving as Vice President of R & D for a medical aesthetics
`company developing products for the dermatology, plastic surgery and otolaryngology
`markets. Responsible for directing development of new products and for interfacing with
`regulatory executives to prepare FDA communications, draft submissions, and present at
`FDA panel meetings.
`
`
`
`
`Anika Therapeutics
`Project Director-Soft Tissue Augmentation
`160 New Boston St., Woburn, MA 01810
`
`
`
`
`
`
`
`2002-2004
`
`
`
`
`
`
`
`
`Responsible for leading development, preclinical and clinical evaluation of a crosslinked
`hyaluronic acid composition for soft tissue augmentation.
`
`Technical Advisor/Consulting
`
`
`2005-Present
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Histogenics Corporation
`830 Winter Street, Waltham, MA 02451
`
`Consulting services to establish a manufacturing facility to produce bovine
`collagen and collagen based sponges for delivery of autologous
`chondrocytes for cartilage repair.
`
`
`
`
`
`
`
`
`
`
`
`
`CollPlant, LTD
`2 Pekeris St
`Rechovot, 76122 Israel
`
`Senior Technical Advisor for CollPlant to assist in development and regulatory
`approval of pharmaceutical and medical device applications for human
`recombinant Type I Collagen derived from plants.
`
`BD Medical-Ophthalmic Systems
`411 Waverly Oaks Road, Waltham, MA 02452
`
`Technical advisor to BD Medical to evaluate acquisition of pharmaceutical and
`medical device products for use during cataract surgery.
`
`
`
`TauTona Research & Development Company
`4040 Campbell Ave., Suite 110
`Menlo Park, CA 94025
`
`
`CV-08/2017
`
`4
`
`

`

`
`
`
`
`2006-2007
`
`
`
`
`Consultant to TauTona on projects to develop, test, and gain FDA approval for
`novel solid state hyaluronic acid compositions for application in aesthetic
`medicine. Product called Aline HA sold to Allergan.
`
`
`
`
`
`Davol, Inc.
`100 Crossings Blvd
`Cranston, RI 02886
`
`Technical advisor on projects to develop, evaluate, and commercialize porcine
`derived surgical meshes for soft tissue repair. Advisory responsibilities including
`coordinating viral clearance evaluations, drafting testing reports and reviewing
`documents for 510(k) submission and for EU approvals. CollaMend Implant
`received 510(k) clearance in 2006.
`
`
`Essex Woodlands Health Ventures
`717 Fifth Avenue, 14th Floor, New York, NY 10022
`
`Consultant to EWHV on drug delivery technologies and other product
`opportunities.
`
`The Innovation Factory
`2750 Premiere Pkwy, Suite 200, Duluth, GA 30097
`
`Consultant to The Innovation Factory on ophthalmic opportunities.
`
`Histogen, Inc.
`9855 Towne Centre Drive, San Diego, CA 92121
`
`Scientific Board Member
`
`
`
`
`
`
`
`
`Consultant
`Clear Vascular, Inc. (Essex Woodlands Health Care Ventures)
`171 Fifth Avenue, 14th Floor
`New York, NY
`10022
`
`Responsible for providing technical expertise in the area of collagen and other
`extracellular matrix constituents and identification of monoclonal and humanized
`antibodies reacting with these targets in vascular tissue, particularly vulnerable plaque.
`
`Founder and Partner
`Xium, LLC
`3 Warwick Drive
`Chelmsford, MA 01824
`
`
`
`
`
`
`
`
`
`
`
`
`1999-2010
`
`CV-08/2017
`
`5
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Co-founder and Chief Technical Officer for a small company developing novel
`techniques to alter the biomechanical properties of intact tissues including cornea, skin
`and cartilage. Awarded Phase I SBIR to develop methods for transcleral drug delivery
`(Collaboration with Dr. Henry Edelhauser)
`
`
`
`
`
`Founder and Partner
`Collagen Matrix Technologies (CMT)
`Boca Raton, FL
`
`Holding company of intellectual property purchased from Collagenesis. Presently in
`discussions with several companies to license IP for dermatology, plastic surgery, and
`otolaryngology.
`
`
`Founder and Partner
`CLN Diagnostics & Therapeutics
`Oklahoma City, OK
`
`Holding company for intellectual property purchased from Collagenesis. Completed
`development agreements with Alcon Laboratories and Genentech; currently developing
`polymeric systems for sustained delivery of drugs to treat back of the eye diseases, i.e.
`age-related macular edema. Recently sold drug delivery patents to an ophthalmology
`company and dissolved partnership.
`
`Independent Consultant to the Medical Device/Tissue
`Engineering Industry
`
`
`
`
`
`
`
`
`
`2001-present
`
`2001-2009
`
`
`
`
`
`
`2001-2006
`
`
`
`
`
`
`
`
`►Consultant to a medical device company to direct development and clinical
` evaluation of a hyaluronic acid formulations for soft tissue augmentation.
`►Consultant to a major dermatology company to assist in development, clinical
` evaluation, and FDA approval of synthetic polymers for application in dermatology
` and plastic surgery.
`►Co-Principal Investigator for a Phase I SBIR project to formulate novel laser-activated
` collagen-based sealants for cardiovascular and orthopedic applications.
`
`►Consultant to a pediatrics pharmaceutical company developing systems for oral
` delivery of pediatric pharmaceuticals.
`
`
`
`
`
`
`Executive Director of Government Programs
`Pericor Science, Inc.
`One Kendall Square
`Cambridge. MA 02139
`
`Principal Investigator on a Phase II STTR contract from the Army Research Office to
`attach an enzyme to skin for protection against G-Type nerve gas. Preparing new
`applications for additional funding to develop and evaluate systems for protection against
`V-Type nerve agents, mustards, and other chemical warfare agents.
`
`
`2001-2002
`
`CV-08/2017
`
`6
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1995-2002
`Closed as of
`1/01/02
`
`1988-1994
`
`1994-1995
`
`
`
`
`1985-1988
`
`
`
`
`
`Chief Scientific Officer, Senior Vice President of R & D,
`Co-founder and Member of Board of Directors
`
`Collagenesis, Inc.
`
`
`
`
`
`500 Cummings Center, 464C
`Beverly, MA 01915
`
`Responsible for Regulatory and Clinical Affairs, Quality Systems, Intellectual Property
`and all R & D in Reconstructive & Plastic Surgery and Urology, Dermatology,
`Ophthalmology, Orthopedics and Drug Delivery. Developed and commercialized four
`products for urology and dermatology/plastic surgery. Initiated and completed marketing
`agreements with two major urology companies; CR Bard and American Medical
`Systems. Developed and directed programs to develop a viscoelastic solution to treat
`osteoarthritis. Directed joint programs to develop delivery systems for recombinant
`human bone morphogenetic protein and for stem cells. Active participant in financing
`activities resulting in investments of more than $60 million from 1996-2001.
`
`Co-founder and Chief Scientific Officer
`Autogenesis Technologies Inc.
`125 Nagog Park, Acton, MA 01720
`
`Responsible for directing R & D in development of tissue-based products for
`ophthalmology, orthopedics, plastic surgery and dermatology. Commercialized
`autologous, tissue-based product for plastic surgery/dermatology. Initiated and completed
`financing agreements with two large multinational corporations.
`
`Managing Director, Biomaterials
`Organogenesis Inc.
`
`
`150 Dan Road
`Canton, MA 02021
`
`Responsible for evaluating the potential market for Organogenesis’ collagen as a raw
`material for the device industry. Decisions regarding formation of a Biomaterials
`Division will be dependent on this evaluation.
`
`
`Vice President, Scientific Affairs
`MedChem Products, Inc.
`Woburn, MA 01801
`
`Responsible for R & D, technical service, and regulatory affairs. Developed currently
`commercialized hyaluronan product for ophthalmic surgery. Prepared regulatory
`submissions for clinical studies (IDE) and product approval (PMA). Active in due
`diligence activities leading to the purchase of a leading collagen-based hemostatic
`product. Initiated clinical trials to evaluate hyaluronan to treat joint disorders.
`
`
`Senior Research Specialist
`3M, St. Paul, MN 55144
`
`
`
`
`
`
`
`
`
`
`
`
`1983-1985
`
`CV-08/2017
`
`7
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Responsible for research and product development in ophthalmology and orthopedics.
`Participant
`in numerous corporate programs
`including
`the Industrial-University
`Relations, Special Programs, and the 3M Innovation Audit Committee.
`
`
`
`
`
`Research Specialist
`3M, St. Paul, MN 55144
`
`Established connective tissue laboratory to develop in vitro and animal models for
`evaluating pharmaceuticals to treat rheumatoid arthritis. Initiated projects to evaluate
`antioxidant agents to treat arthritis.
`
`
`
`Lecturer and Staff Member
`University of Minnesota, School of Dentistry
`
`Lecturer in School of Dentistry on connective tissue biochemistry
`
`
`Research Biochemist/Principle Research Biochemist/
`Group Leader in Cell & Molecular Biology
`Battelle Memorial Institute, Columbus, OH 43201
`
`Directed research in many projects including NIH grants on Mechanisms of Sea Mussel
`Adhesive Formation, Electrically Induced Osteogenesis, Electric Stimulation of Bone
`Healing, In vitro Techniques to Monitor Pesticide Toxicity.
`Directed Arthritis Foundation Grants to examine the mechanisms of action of D-
`Penicillamine in treatment of RA.
`
`Honors:
`
`
`1979-1983
`
`1980-1985
`
`1972-1979
`
`3M Circle of Technical Excellence
`Who’s Who in Frontier Science & Technology
`Who’s Who in Medicine & Technology
`Who’s Who Science and Engineering
`Who’s Who in America
`
`
`
`
`BOOKS AND CHAPTERS
`
`DeVore, DP, The Etiology of Scarring and Wrinkle Formation, In: Applications of
`Biomaterials in Facial Plastic Surgery, Eds. Glasgold, A and
`Silver, F, CRC Press, 1991
`
`DeVore, DP, Collagen as An Ophthalmic Biomaterial, In: Encyclopedic
`Handbook of Biomaterials and Bioengineering, Eds. Wise, DL, Trantolo, DJ,
`Altobelli, DE, Yaszemski, MJ, Gresser, JD, and Schwartz, ER, Marcel
`Dekker, New York, Chapter 45, pp 1233, 1995.
`
`CV-08/2017
`
`8
`
`

`

`
`
`
`
`
`
`
`
`DeVore, DP, Kelman, CD, Fagien, S, and Casson, P. Autologen: Autologous,
`Injectable Dermal Collagen. Chapter 65. In Principles and Practices of Ophthalmic
`Plastic & Reconstructive Surgery, Volume 1., W.B. Saunders Company, New York,
`1995, pp. 670-675.
`
`Eiferman, RA and DeVore, DP, Phototherapeutic Keratectomy, Chapter 37, In: Laser
`Corneal Surgery, Eds. R Elander, LF Rich & JB Robin, WB Saunders Co, 1997, pp. 379-
`388.
`
`Leopoldo, S, DeVore, DP, Eiferman, RA, DeWoolfson, B, Stewart, CW, Swartz, TS, and
`Wang, M. New and Future Treatments: Excimer Laser Lamellar Keratoplasty and
`Advanced Crosslinking, Chapter 18, In: Keratoconus & Keratoectasia: Prevention,
`Diagnosis, and Treatment, Ed. M. Wang and TS Swartz, Slack Inc., 2010, pp 177-185.
`
`Cummings, A.B, Sinjab, M.M., Hatch, K.M., Talamo, J., Randleman, B., Kanellopoilos,
`A.J., Asimellis, G., Sakla, H., Altroudi, W., Rabinowitz, Y.S., Kilic, A., Ribinfeld, R.S.,
`Ambrosio, R., El-Kateb, M, DeVore, D.P., Ross, M.A., DeWoolfson, B.H., and Dryjski,
`O. Combined Corneal Crosslinking and Other Procedures: Indications and
`Application Models. Chapter 4. In: Corneal Collagen Crosslinking, Ed. M.M Sinjab and
`A. Cummings. Springer International Publishing, Switzerland, 2016
`
`
`
`
`CV-08/2017
`
`9
`
`

`

`
`
`
`
`
`
`
`
`
`
`BIBLIOGRAPHY
`
`
`Original Papers, Chapters, Proceedings
`
`1.
`
`DeVore, DP and Solberg, M. Oxygen uptake in postrigor bovine muscle, J. Food
`Science, 39:22. 1974
`
`DeVore, DP, Walter, JL, Carter, SD, and Boatman, JS.
`Glycosaminoglycans, collagen and elastin of the aorta of normal and hypothyroid
`neonate swine, The Physiologist, 18:721, 1974
`
`Walter, JL, DeVore, DP, Carter, SD, and Boatman, JS. Regional
`permeability of normal and hypothyroid neonate swine, The Physiologist,
`18:719, 1974
`
`DeVore, DP and Solberg, M. A study of rate-limiting factors in the
`respiratory consumption of intact bovine muscle, J. Food Science,
`40:561, 1975
`
`DeVore, DP, Sheridan, MA, Pitman, JS, and Hutson, TB. Aldrin toxicity
`in cultured mammalian cells, The Pharmacologist, 16:721, 1976
`
`DeVore, DP, Hutson, TB, Sheridan, MA, and Pitman, JS. Pesticide
`toxicity in cultured mammalian cells, Toxicol. & Applied Pharmacol.,
`41:169, 1977
`
`DeVore, DP, Gruebel, RJ, and Hutson, TB. The modulation of synovial
`collagenase by D-Penicillamine, Fed. Proceedings, 37:993, 1978
`
`DeVore, DP and Gruebel, RJ. Dityrosine in adhesive formed by the sea
`mussel, Biochem. Biophys. Res. Commun. 80:993, 1979
`
`DeVore, DP, Gruebel, RJ, Hutson, TB, and Turner, RH. Effects of
`D-Penicillamine on lymphocyte modulation of collagenase production,
`Agents & Actions, 9:172, 1979
`
`DeVore, DP. Effects of D-Penicillamine on synovial collagenase
`production, Scand. J. Rheumatology, Supplement-Proceedings of the
`2nd Bertine Koperberg Conference on Fundamental Studies on Penicillamine for
`Rheumatoid Diseases, September, 1978
`
`DeVore, DP, Houchens, DP, Overjera, OO, Dill, GS, and Hutson, TB.
`Collagenase inhibitors retarding invasion of a human tissue tumor in nude
`mice, Exp. Cell Biology, 48:367, 1980
`
`DeVore, DP. Inhibitors of connective tissue degradation and their
`potential as antiarthritics, Ann. Report of Medicinal Chemistry, 17:175,
`1982
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`10.
`
`11.
`
`12.
`
`CV-08/2017
`
`10
`
`

`

`
`
`
`
`
`
`
`
`Engebretson, GH, Schachtele, CF, Sauk, JJ, and DeVore, DP. Isolation of
`adhesive proteins from the sea mussel, Mytilus edulis, Comp. Biochem. &
`Physio., Part B., 77B:201, 1984
`
`DeVore, DP, Engebretson, GH, Schachtele, CF, and Sauk, JJ.
`Characterization of collagen from sea mussel byssal thread, Comp. Biochem. &
`Physiol., Part B., 77B:529, 1984
`
`DeVore, DP, Engebretson, GH, Schachtele, CF, and Sauk, JJ. Isolation
`characterization of adhesive proteins secreted by the sea mussel, Mytilus edulis.
`Proceedings of the Sixth International Congress on Marine Corrosion and
`Fouling, Athens, Greece, September, 1982
`
`DeVore, DP. Biology of connective tissue and relevance to cosmetic
`technology, Review: Cosmetic and Toiletries, 99:27, 1984
`
`DeVore, DP, Scholtz, MT, Scherrer, RA, and Medenhall, HV. Viscoelastic
`collagen for use in ophthalmic surgery, Proceedings of the First Atlantic
`Congress on the Future of Collagen as A Biomaterial, Lyon, France, 1985, p253
`
`Reiter, MJ, Schwartzmiller, DH, Swingle, KF, Moore, GI. Goldlust, MB,
`Heghinian, K, DeVore, DP, Choy, B, and Weppner, WA. Comparison of anti-
`inflammatory compounds in the carrageenan induced paw edema model and the
`passive arthritis model utilizing the same animal, Life Sciences, 36:1339, 1985
`
`Grosh, SK, Hanke, CW, Gibbons, DG, and DeVore, DP. Variables
`affecting the results of xenogenic collagen implantation in an animal model, J.
`Amer. Acad. Dermatol., 13:792, 1986
`
`13.
`
`14.
`
`15.
`
`16.
`
`17.
`
`18.
`
`19.
`
`
`20.
`
`21.
`
`22.
`
`23.
`
`24.
`
`DeVore, DP. The use of hyaluronate in vitreous surgery, Proceedings of
`the Second International Symposium of Viscoelastic Materials, Manchester,
`England, 1986
`
`Leith, MM, Kuo, J-W, Loftus, SA, Keates, EU, and DeVore, DP.
`Comparison of the properties of AMVISC and Healon. J. Cataract Refract.
`Surg., 13:534, 1987
`
`Loftus, SA, Montplaisir, JM, Juo, J-W, and DeVore, DP. Comparison
`of the properties of hyaluronate products used in the treatment of joint
`dysfunction in horses, J. Equine Vet. Science, 8:117, 1988
`
`DeVore, DP and Loftus, SA. Properties of hyaluronate solutions and their
`use as biomaterial implants, Materials Res. Society Proceedings, 110:455,
`1989
`
`DeVore, DP. The Etiology of Scarring and Wrinkle Formation, In:
`Applications of Biomaterials in Facial Plastic Surgery, Eds. Glasgold, A and
`Silver, F, CRC Press, 1991
`
`
`CV-08/2017
`
`11
`
`

`

`
`
`
`
`
`
`
`25.
`DeVore, DP. Long-term compatibility of intraocular lenses implant
`materials, J. Long-term Effects of Medical Implants, 1:205, 1991
`
`Emery, R, DeVore, D., and DeVore, DP. Hyaluronic acid clearance from
`immunologically induced synovitic rabbit knees, J. Dental Res. 70:465, 1991
`
`Scott, JB, DeVore, DP, Eiferman, RA, and Nordquist, RE. Collagen
`modular fluids for use during photoablation keratectomy, Invest. Ophthalmol. &
`Vis. Sci, 33:764, 1992
`
`DeVore, DP, Scott, JB, and Kelman, CD. Preliminary evaluation of a
`collagen-based corneal prosthesis, Invest. Ophthalmol. & Vis. Sci., Supplement,
`33:993, 1992
`
`Fagien, S, Kelman, CD, DeVore, DP, and Casson, P. Soft tissue
`augmentation with autologous injectable dermis, Amer. Soc. Ophthalmol Plast. &
`Reconstructive Surg., 1992
`
`Kornmehl, EW, Bredvik, BK, Kelman, CD, Raizman, MB, and
`DeVore, DP. Biocompatibility of a collagen corneal allograft derived from
`rabbit dermis, Invest. Ophthalmol. & Vis. Sci., Supplement, 34:1088, 1993
`
`DeVore, DP, Scott, JB, Nordquist, RE, Eiferman, RA, and Hoffman, RS.
`Evaluation of variable ablation collagen gels for excimer laser keratectomy,
`Invest. Ophthalmol & Vis. Sci., Supplement, 34:1245, 1993
`
`DeVore, DP, Kelman, CD, Stark, W, Green, WR, Bredvik, B, and
`Kornmehl, W. Evaluation of collagen-based corneal grafts in the rabbit model,
`Refractive & Corneal Surg., 9:208, 1993
`
`26.
`
`27.
`
`28.
`
`29.
`
`30.
`
`31.
`
`32.
`
`
`
`
`
`33.
`
`34.
`
`35.
`
`36.
`
`37.
`
`DeVore, DP, Bredvik, BK, Raizman, MB, and Kornmehl, EW, Evaluation
`of collagen-based corneal allografts in rabbits, Proceedings of First International
`Symposium of Ophthalmology, Bordeaux, Pp 112, 1993
`
`DeVore, DP, Preparation and evaluation of collagen-based ophthalmic
`Implants, Proceedings of the First International Symposium of
`Ophthalmology, Bordeaux, Pp 113, 1993.
`
`Kwait, PS, Eiferman, RA and DeVore, DP. Collagen gels as drug delivery
`vehicles and tissue adhesives, Invest. Ophthal. & Visc. Sci., Supplement,
`35:2190, 1994
`
`DeVore, DP, Hughes, EA, and Fagien, S. Autologous collagen fibers for
`tissue augmentation, Invest. Ophthal. & Vis. Sci., 35:1530, 1994
`
`DeVore, DP., Hughes, E, and Scott, JB. Effectiveness of injectable filler
`materials for smoothing wrinkle lines and depressed scars, Med. Progress
`through Technology, 20: 243, 1994
`
`
`
`CV-08/2017
`
`12
`
`

`

`38.
`
`39.
`
`40.
`
`41.
`
`42.
`
`43.
`
`44.
`
`
`
`
`
`
`
`
`
`DeVore, DP. Collagen as an ophthalmic biomaterial, In: Encyclopedic
`Handbook of Biomaterials and Bioengineering, Eds. Wise, DL, Trantolo, DJ,
`Altobelli, DE, Yaszemski, MJ, Gresser, JD, and Schwartz, ER, Marcel Dekker,
`New York, Chapter 45, pp 1233, 1995
`
`DeVore, DP, Scott, JB, Nordquist, RE, Hoffman, RS, and Eiferman, RA.
`Rapidly polymerized collagen gel as a smoothing agent for use in excimer laser
`photoablation, J. Refract. Surg, 11:50, 1995
`
`Kornmehl, EW, Bredvik, BK, Raizman, MB, Kelman, CD and DeVore,
`DP. In Vivo Evaluation of collagen corneal allograft derived from rabbit dermis.,
`J. Refract. Surg., 11, pps. 502-506, 1995 (Nov.-Dec.)
`
`DeVore, DP, Kelman, CD, Fagien, S, and Casson, P. Autologen:
`Autologous, injectable dermal collagen. Chapter 65. In: Principles and
`Practices of Ophthalmic Plastic & Reconstructive Surgery, Volume 1.,
`W. B. Saunders Company, New York, 1995, pp. 670-675
`
`Cendron, M, Sant, GR, Klauber, GT, and DeVore, DP. Endoscopic
`injection of autologous collagen for the treatment of vesicoureteral reflex.
`Proceedings of the 2nd. International Congress of Endoscopic Paediatric
`Treatment of Vesicoureteral Reflux, Basel, 1993
`
`Cendron, M, Sant, GR, Klauber, CT, Connolly, R, DeVore, DP. The
`biological behavior of autologous collagen injected into the rabbit bladder. J. of
`Urology, 154: 808, 1995
`
`Cendron, M, DeVore, DP, and Klauber, GT. Autologous collagen and
`applications in pediatric urology, Dialogues in Pediatric Urology, 18(11),
`November, 1995
`
`
`45. DeVore, DP, Skelnik, D, and Kornmehl, EW. Epithelial cell attachment
`to collagen-based lenses, Proceedings of the Fifth World Biomaterials Congress,
`Toronto, Canada, 1996
`
`46. Eiferman, RA and DeVore, DP. “Phototherapeutic keratectomy”, Chapter
`37, In Laser Corneal Surgery, Eds. R Elander, LF Rich & JB Robin, WB
`Saunders Co, 1997, pps. 379-388
`
`47. Cozzolino, DJ, MD, Cendron, M, MD, FAAP, DeVore, DP, Ph.D., and
`Hoops DJ, DVM, Ph.D. Long-term Persistence of Autologous Collagen in The
`Bladder Wall of Rabbits, Neurourology and Urodynamics, 18: 487-495, 1999
`
`
`48. DeVore, DP, “Human Collagen Matrices for Tissue Augmentation”,
`Chapter 16, In: Bioengineering of Skin Substitutes”, IBC Library Series,
`Ed. LM Savage, 1998, Pp. 93-128.
`
`
`
`
`
`CV-08/2017
`
`13
`
`

`

`
`
`
`
`
`
`
`
`
`49. Saadeh, PB, Cocker, RS, Falk, AN, DeVore, DP, Mehrara, BJ,
`McCormick, SA, Steinbrech, DS, Rowe, NM, McCarthy, JG, Gittes, GK, and
`Longaker, MT, Repair of A Critical Size Defect in The Rat mandible Using
`Allogeneic Type I Collagen, Plastic Surgery Forum, 1999
`
`
`50. DeVore, DP, Skelnik, D, and Kornmehl, EW, Evaluation of Collagen
`Based Allografts: Enhancement of Epithelialization, Ann. Del Instituot
`Barraquer, Vol. XXVIII-Supp.: 175-176, 1999
`
`51. Silver, FH, Freeman, J and DeVore, DP, Viscoelastic Properties of Human
` Skin and Processed Dermis, Skin Research & Technology, 7: 18-23, 2001
`
`
`
`
`
`
`
`
`
`
`
`52.
`
`53.
`
`Silver, FH, Seehra, GP, Freeman, JW and DeVore, DP, Viscoelastic Properties of
`Young and Old Dermis: A Proposed Molecular Mechanism for Elastic Energy
`Storage in Collagen and Elastin, J. Appl. Polymer Sci., 2002. 86: 1978-1985.
`
`Pierre B. Saadeh, MD, Rohit K. Khosla, Babak J. Mehrara, MD, Douglas S. Steinbrech,
`MD, Steven A. McCormick, MD, Dale P. DeVore, PhD, and Michael T. Longaker, MD,
`Repair of a Critical Size Defect in the Rat Mandible Using Allogenic Type I Collagen, J.
`Craniofacial Surgery, 12(6): 573-579, 2001.
`
`
`DeVore, DP, Veis, A, Dahl, T, and Hughes, KG, Collagen Fibril
`Formation at Microgravity Conditions: Fibrillogenesis under Diffusion Control,
`Proceedings of the Microgravity Transport Processes in Fluid, Thermal,
`Biological, and Materials Sciences, Banff, Alberta, Canada, September 30 to
`October 5, 2001
`
`55. DeVore, DP, Fabrication of an Artificial Cornea-An Engineering
`Challenge, In: Frontiers in Biomedical Polymers, Ed: S. Farmer and R.
`Ottenbrite, Technomic Publishing Co., Inc.
`
`
`54.
`
`56. Eiferman, RA, DeVore, DP and Nordquist, RE, Reversible in situ Formation of a
`Collagen Canalicular Plug, Invest. Ophthalmol. & Visc. Sci., Supplement,
`ARVO, 2002.
`
`
`57. Silver FH, DeVore D, Siperko LM., Invited Review: Role of mechanophysiology
`in aging of ECM: effects of changes in mechanochemical transduction, J Appl
`Physiol. 2003 Nov; 95 (5):2134-41.
`
` 58.
`
`Lanzafame, RJ, Stadler, I, Brondon, P, Soltz, BA, and DeVore, DP, Preliminary
`Assessment of Postoperative Adhesion Formation after Laser-Assisted Mesh
`Fixation to the Peritoneal Surface. J Laparoendoscopy Adv Surg Tech A. 2005
`Apr;15(2):105-11.
`
`
`59. Lanzafame, RJ, Soltz, BA, Stadler, I, Soltz, MA, Soltz, R, and DeVore, DP.
`Acute Tensile Strength Analysis of Collagen Solder for Mesh Fixation to the
`Peritoneal Surface. Surg Endosc. 2005 Feb;19(2):178-83.
`
`
`
`
`CV-08/2017
`
`14
`
`

`

`
`
`
`60. Lanzafame RJ, Brondon P, Stadler I, Devore DP, Soltz R, Soltz BA, Histologic
` assessment of mesh fixation following laser-assisted tissue soldering in a lapine
` model. Lasers Surg Med. 2005 Aug; 37(2):130-7.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`61. Coleman, KM., Voigts, R., DeVore, DP, Termin, P., and Coleman, WP III.
` Neocollagenesis following injection of calcium hydroxylapatite composition in
` a canine model. Dermatol. Surg. 2008 34: S53-55
`
`62. Ruff, KJ, DeVore, DP, Leu, MD, and Robinson, MA Eggshell Membrane: A
`possible new natural therapeutic for joint and connective tissue disorders. Results
`from two open-label human clinical studies. Clinical Interventions in Aging.
`2009. 4:235-240
`
`63. Ruff, KJ, Winkler, A, Jackson, RW, DeVore, DP, and Ritz, BW. Eggshell
`
`Membrane in the treatment of pain and stiffness from osteoarthritis of the knee:
`
`A randomized, multicenter, double-blind, placebo-controlled clinical study.
`
`Clin. Rheumatol. DOI 10.1007/s10067-009-1173-4 Published Online
`
`
`64. Voigts, R, DeVore, DP, and Grazer, JM. Dispersion of Calcium Hydroxylapatite
` Accumulations in the Skin: Animal Studies